Search
Somapacitan
go.drugbank.com/drugs/DB15093ApprovedInvestigational[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. … Somapacitan, also known as NNC0195-0092,[A219136] is a growth hormone analog indicated to treat adults with growth hormone deficiency.
Venetoclax
go.drugbank.com/drugs/DB11581ApprovedInvestigationalProteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process [A18565], [A18566]. … Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries [A40022].
Bulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigationalHepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality. … It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency.
Zoledronic acid
go.drugbank.com/drugs/DB00399ApprovedInvestigationalZoledronic acid, or CGP 42'446,[A203120] is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid]. … [L13712,L13715,L13721] Zoledronic acid was first described in the literature in 1994.[A203120] Zoledronic acid was granted FDA approval on 20 August 2001.[L13712]
Cyclandelate
go.drugbank.com/drugs/DB04838ApprovedWithdrawnCyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries. … A direct-acting smooth muscle relaxant used to dilate blood vessels. It may cause gastrointestinal distress and tachycardia.
Zopiclone
go.drugbank.com/drugs/DB01198ApprovedInvestigationalIn addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties. … Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors.
Muromonab
go.drugbank.com/drugs/DB00075ApprovedInvestigationalWithdrawnMore specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. … Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens.
Categories: CD3 Receptor AntagonistsBetahistine
go.drugbank.com/drugs/DB06698ApprovedInvestigational[A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy. … It is thought to reduce symptoms through its actions on histamine receptors.
Dasabuvir
go.drugbank.com/drugs/DB09183ApprovedThe binding sites for non-nucleoside NS5B inhibitors are poorly conserved across HCV genotypes leading to the restriction of Dasabuvir's use to genotype 1 only. … Dasabuvir is a non-nucleoside NS5B inhibitor which binds to the palm domain of NS5B and induces a conformational change which renders the polymerase unable to elongate viral RNA [FDA Label].
Chlorquinaldol
go.drugbank.com/drugs/DB13306Approved[F4549] It was marketed in the 1950s as an iodine-free alternative which was also unrelated to sulfa drugs or hormones. … Chlorquinaldol is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.[F4552]